Investments
11Portfolio Exits
19Funds
16Partners & Customers
1About Duke Street
Duke Street is a private equity firm that invests in Western European mid-market companies across five sectors: Consumer, Business Services, Healthcare, Financial Services, and Industrial & Engineering.
Duke Street Headquarter Location
Nations House 103 Wigmore Street
London, England, W1U 1QS,
United Kingdom
+44 (0)20 7663 8500
Duke Street Web Traffic
Duke Street Rank
Latest Duke Street News
May 25, 2022
25/05/2022 - 3 minutes The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline into clinical studies. The company aims to deliver next-generation cancer therapies based on DNA damage repair (DDR) and immuno-oncology and claims to have made rapid development progress. It has several drug discovery programs targeting the key enzymes that control DDR and immune system activation. Poly (ADP-ribose) polymerases, or PARPs, are a type of enzyme that helps repair DNA damage in cells. PARP inhibitors work by preventing cancer cells from carrying out vital DNA repairs inside the cell. Duke Street Bio was founded in 2020 by the management team behind the Scottish firm IOmet Pharma. IOmet Pharma, which developed medicines for cancer with a focus on immunotherapy and metabolism, went on to be bought by US-based MSD in 2016. “We focused on immuno-oncology at IOmet and it made sense to continue that with Duke Street,” Alan Wise, Duke Street Bio chief executive and co-founder, told us. Related Content “And then we’ve got involved in the DNA damage repair space as well. There’s a lot of connectivity between DDR and immuno-oncology. There’s a lot of emerging evidence to show that deficiencies or genetic vulnerabilities in DDR can impact very positively on orchestrating an immune response.” While marketed DDR and immuno-oncology therapies only work in limited patient populations, the molecules Duke Street Bio is developing could significantly expand the number of patients that could benefit from these types of treatment approaches, he said. The startup’s DDR program targets PARP1, an enzyme that’s essential for initiating various forms for DNA repair and which has been clinically verified. The company says its second-generation approach means it can deliver safer therapeutics that can be used in combination with chemotherapies and targeted agents. The immuno-oncology program targets PARP7, an enzyme that has recently emerged as a key regulator of the immune system in the tumor microenvironment. Inhibitors of PARP7 can create a hostile immune environment to the cancer that enables tumor targeting and elimination. Duke Street Bio’s goal is to reprogram the cancer cell and tumor microenvironment biology to harness the natural power of the body’s immune system to fight cancer. “There is significant therapeutic opportunity in further exploration of the cellular signaling pathways controlled by the PARP family of enzymes,” said Elliott Sigal, advisor to Duke Street Bio and former chief scientific officer and president of research and development at Bristol Myers Squibb. Related Content Additional programs focused on related enzymes are at the validation phase, the company said. The startup has a similar hybrid business model to that of IOmet Pharma, with a small internal team and the outsourcing of experimental work to contract research organizations around the world, some of which the team has worked with for over a decade. “We’ve got the track record so fundraising has been relatively straightforward,” Peter Trill, chairman and co-founder of Duke Street Bio, told us. Other companies researching cancer therapies based on DNA repair include Artios, which is developing DNA damage response inhibitors and raised €129M in a Series C funding round last year. Breakpoint Therapeutics , a spinoff from German biotech Evotec, aims to develop drugs that kill cancer cells by sabotaging their DNA repair machinery. Meanwhile, Paris-based Onxeo is trialing a cancer treatment that interferes with DNA repair mechanisms. Cover image via Shutterstock
Duke Street Investments
11 Investments
Duke Street has made 11 investments. Their latest investment was in Parabis Group as part of their Private Equity - II on December 12, 2014.
Duke Street Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
12/5/2014 | Private Equity - II | Parabis Group | $20.27M | No | 1 | |
2/6/2012 | Private Equity | Parabis Group | Yes | 1 | ||
4/15/2010 | Growth Equity | Oasis Healthcare | $45.82M | Yes | Undisclosed Investors | 1 |
1/31/2004 | Private Equity | |||||
8/7/2000 | Private Equity |
Date | 12/5/2014 | 2/6/2012 | 4/15/2010 | 1/31/2004 | 8/7/2000 |
---|---|---|---|---|---|
Round | Private Equity - II | Private Equity | Growth Equity | Private Equity | Private Equity |
Company | Parabis Group | Parabis Group | Oasis Healthcare | ||
Amount | $20.27M | $45.82M | |||
New? | No | Yes | Yes | ||
Co-Investors | Undisclosed Investors | ||||
Sources | 1 | 1 | 1 |
Duke Street Portfolio Exits
19 Portfolio Exits
Duke Street has 19 portfolio exits. Their latest portfolio exit was Voyage Care on January 14, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
1/14/2022 | Acquired | 4 | |||
4/8/2019 | Merger | 1 | |||
12/13/2017 | Acquired | 3 | |||
Date | 1/14/2022 | 4/8/2019 | 12/13/2017 | ||
---|---|---|---|---|---|
Exit | Acquired | Merger | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 | 1 | 3 |
Duke Street Acquisitions
40 Acquisitions
Duke Street acquired 40 companies. Their latest acquisition was COMPO - Consumer Business on June 05, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
6/5/2021 | Acquired Unit - Fin | 2 | ||||
6/3/2021 | Acq - Fin | 4 | ||||
6/3/2021 | Acq - Fin - II | 2 | ||||
6/3/2019 | ||||||
6/3/2019 |
Date | 6/5/2021 | 6/3/2021 | 6/3/2021 | 6/3/2019 | 6/3/2019 |
---|---|---|---|---|---|
Investment Stage | |||||
Companies | |||||
Valuation | |||||
Total Funding | |||||
Note | Acquired Unit - Fin | Acq - Fin | Acq - Fin - II | ||
Sources | 2 | 4 | 2 |
Duke Street Fund History
16 Fund Histories
Duke Street has 16 funds, including Duke Street Fund VI.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
12/31/2007 | Duke Street Fund VI | 1 | |||
6/28/2007 | DSC VI | Diversified Private Equity | Closed | $1,154.02M | 1 |
8/2/2004 | Duchess III | Diversified Private Equity | Closed | $548.96M | 1 |
4/25/2003 | Duchess II | ||||
6/1/2002 | DSC V LP |
Closing Date | 12/31/2007 | 6/28/2007 | 8/2/2004 | 4/25/2003 | 6/1/2002 |
---|---|---|---|---|---|
Fund | Duke Street Fund VI | DSC VI | Duchess III | Duchess II | DSC V LP |
Fund Type | Diversified Private Equity | Diversified Private Equity | |||
Status | Closed | Closed | |||
Amount | $1,154.02M | $548.96M | |||
Sources | 1 | 1 | 1 |
Duke Street Partners & Customers
1 Partners and customers
Duke Street has 1 strategic partners and customers. Duke Street recently partnered with Goldman Sachs, and Arcano Capital on March 3, 2016.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
3/31/2016 | Partner | United States, and Spain | Duke Street teams up with Goldman Sachs and Arcano to restructure Fund VI - Duke Street • Peter Taylor , managing partner , joined Duke Street in 1996 after qualifying as a chartered accountant and working at Bridgepoint . | 2 |
Date | 3/31/2016 |
---|---|
Type | Partner |
Business Partner | |
Country | United States, and Spain |
News Snippet | Duke Street teams up with Goldman Sachs and Arcano to restructure Fund VI - Duke Street • Peter Taylor , managing partner , joined Duke Street in 1996 after qualifying as a chartered accountant and working at Bridgepoint . |
Sources | 2 |
Duke Street Team
6 Team Members
Duke Street has 6 team members, including former Chief Executive Officer, Ian Hazelton.
Name | Work History | Title | Status |
---|---|---|---|
Ian Hazelton | Royal Bank of Scotland | Chief Executive Officer | Former |
Edmund Truell | Chief Executive Officer | Former | |
Frederic Chauffier | Managing Director | Former | |
Graham Lee | Managing Director | Former | |
Ervin Schellenberg | Managing Director | Former |
Name | Ian Hazelton | Edmund Truell | Frederic Chauffier | Graham Lee | Ervin Schellenberg |
---|---|---|---|---|---|
Work History | Royal Bank of Scotland | ||||
Title | Chief Executive Officer | Chief Executive Officer | Managing Director | Managing Director | Managing Director |
Status | Former | Former | Former | Former | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.